FIELD: medicine.
SUBSTANCE: invention refers to medicine, in particular, to gynaecology, and can be used for diagnostics of probability of local inflammation development in myomatous nodule. For this purpose, an average level of immunoreactivity of blood serum samples to Spr-06 antigen is determined. If the average level of immunoreactivity to SPR-06 antigen varies from +11 % to +20 % or from -21 % to -30 %, hysteromyoma with local inflammation development in myomatous nodule is predicted. If the average level of immunoreactivity to SPR-06 antigen is more than +20 % or less than -30 % dysnutrition in myomatous nodule is predicted, this is an indication for surgical service.
EFFECT: using the given method enables predicting hysteromyoma with clinical symptoms developing based on blood analysis data.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING INFERTILITY IN FEMALES SUFFERING FROM UTERINE MYOMA | 2014 |
|
RU2585367C1 |
| METHOD FOR PREDICTING HEMORRHAGES DEVELOPING IN FEMALES SUFFERING FROM HYSTEROMYOMA | 2014 |
|
RU2592374C2 |
| METHOD FOR PREVENTING PERITONEAL ADHESIONS AFTER MYOMECTOMY | 2019 |
|
RU2730943C2 |
| METHOD FOR SURGICAL TREATMENT OF METRA FIBROIDS IN WOMEN OF REPRODUCTIVE AGE | 2020 |
|
RU2750911C1 |
| METHOD FOR TREATING HYPERPLASTIC ENDOMETRIAL PROCESSES COMBINED WITH UTERINE MYOMA | 2006 |
|
RU2317103C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATING UTERINE FIBROIDS USING FUS-MRI ABLATION IN THE PATIENTS OF REPRODUCTIVE AGE AT THE STAGE OF PREGNANCY PLANNING | 2019 |
|
RU2716337C1 |
| METHOD FOR PREDICTION OF RISK OF RECURRENCE OF SYMPTOMATIC UTERINE MYOMA AFTER SELECTIVE EMBOLIZATION OF UTERINE ARTERIES | 2021 |
|
RU2766809C1 |
| METHOD OF PREOPERATIVE PREPARATION FOR MYOMECTOMY | 2024 |
|
RU2826765C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSTICS OF NODULAR ADENOMYOSIS AND UTERINE MYOMA | 2021 |
|
RU2787804C1 |
| METHOD FOR PREDICTING THE PROBABILITY OF DEVELOPMENT OF PROLIFERATING UTERUS MYOMA | 2018 |
|
RU2676035C1 |
